Johnson & Johnson (JNJ) Panoramica del titolo
Johnson & Johnson, insieme alle sue consociate, è impegnata nella ricerca e nello sviluppo, nella produzione e nella vendita di una serie di prodotti nel settore sanitario in tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 3/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 5/6 |
JNJ Community Fair Values
Create NarrativeSee what 755 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Concorrenti di Johnson & Johnson
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$226.71 |
| Massimo di 52 settimane | US$251.71 |
| Minimo di 52 settimane | US$149.04 |
| Beta | 0.26 |
| Variazione di 1 mese | -3.19% |
| Variazione a 3 mesi | -6.88% |
| Variazione di 1 anno | 49.81% |
| Variazione a 3 anni | 42.67% |
| Variazione a 5 anni | 32.61% |
| Variazione dall'IPO | 36,173.66% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento della narrazione • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.Aggiornamento della narrazione • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.Seeking Alpha • Apr 17
Johnson & Johnson: Why I See Downside Ahead
Summary Johnson & Johnson only slightly raised its 2026 financial guidance. So JNJ expects its operational sales to be between $99.7 billion and $100.7 billion, up from $99.5 billion to $100.5 billion. In my view, this is due to the sharp decline in demand for Stelara, JNJ's former "cash cow" in the immunology franchise. Moreover, JNJ's acquisition of Intra-Cellular Therapies for $14.6 billion doesn't meet my expectations, as Caplyta sales grew by only 8.4% quarter-on-quarter to $270 million. Further in this article, you'll learn about additional reasons why I believe Johnson &Johnson's risk/reward profile is still unattractive. Read the full article on Seeking AlphaAggiornamento della narrazione • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.
Nuova narrazione • Mar 30
Johnson & Johnson (JNJ): The $100 Billion Revenue Frontier and the MedTech Evolution
Johnson & Johnson (JNJ) is currently trading at $242.83 USD on the NYSE as of the afternoon session on March 30, 2026, reflecting a steady 1% gain for the day. After a transformative 2025 that saw the full integration of its "pure-play" healthcare strategy following the Kenvue spin-off, the company has entered 2026 with significant momentum.Aggiornamento della narrazione • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.
Nuova narrazione • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.Aggiornamento della narrazione • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.Aggiornamento della narrazione • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.Aggiornamento della narrazione • Jan 27
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward
Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.
Nuova narrazione • Jan 25
Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company that develops and sells pharmaceuticals and medical devices across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Jan 09
JNJ: Ortho Separation And Talc Risks Will Shape Balanced Forward Risk Reward
Analysts have nudged their fair value estimate for Johnson & Johnson slightly higher to about US$211 per share, reflecting updated views on revenue growth, profitability, and future P/E assumptions informed by recent price target increases and supportive research commentary on the company's pipeline and planned ortho separation. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of optimism around the pipeline, margin profile, and planned ortho separation, alongside ongoing attention to litigation and product risk.Aggiornamento della narrazione • Dec 19
JNJ Future Portfolio Separation And Litigation Resolution Will Shape Balanced Risk Reward Outlook
Analysts have raised their average price target on Johnson & Johnson by about $7 to roughly $209, reflecting slightly faster expected revenue growth, a modestly higher future earnings multiple, and confidence that portfolio reshaping and pipeline execution can offset near term margin pressure. Analyst Commentary Street research on Johnson & Johnson has turned incrementally more constructive, with multiple firms lifting price targets in response to stronger fundamentals and portfolio actions that are viewed as supportive of a faster growth profile.Aggiornamento della narrazione • Dec 05
JNJ: Future Reorganization And Litigation Outcomes Will Shape Risk Reward Balance
The analyst price target for Johnson & Johnson has been nudged higher, with fair value rising from approximately $200.82 to $202.54 per share, as analysts highlight slightly stronger long term revenue growth, modestly higher profit margins, and a richer future P/E multiple supported by an improving innovation pipeline and portfolio reshaping efforts. Analyst Commentary Recent research updates reflect a broadly constructive stance on Johnson & Johnson, with a growing number of firms highlighting improving fundamentals, a stronger growth profile, and a more compelling risk reward setup following the latest results and guidance.Aggiornamento della narrazione • Nov 21
JNJ: Upcoming Business Reorganization and Legal Risks Will Influence Future Performance
Johnson & Johnson's analyst price target has increased slightly from $199.56 to $200.82, as analysts cite stronger-than-expected sector performance and a constructive long-term industry outlook, which support the adjustment. Analyst Commentary Recent analyst commentary on Johnson & Johnson highlights a variety of perspectives related to the company's valuation, strategic direction, and future growth potential.Aggiornamento della narrazione • Nov 05
JNJ: Upcoming Portfolio Shifts and Legal Uncertainties Will Shape Risk-Reward Balance
Johnson & Johnson's fair value estimate has increased by $1.52 to $199.56, as analysts point to improving core growth metrics, recent strong quarterly results, and expectations for higher margins following portfolio changes. Analyst Commentary Recent Street research reveals a mix of optimism and caution among analysts following Johnson & Johnson’s latest results, portfolio changes, and evolving sector dynamics.Aggiornamento della narrazione • Oct 22
Analyst Commentary Drives Higher Valuation Targets for Johnson & Johnson Amid Positive Company Developments
Analysts have raised their fair value price target for Johnson & Johnson from approximately $185.13 to $198.03. They cite robust quarterly results, upcoming product launches, and anticipated growth and margin improvements from the company's business transformation initiatives as key reasons for the adjustment.Rendimenti per gli azionisti
| JNJ | US Pharmaceuticals | US Mercato | |
|---|---|---|---|
| 7D | 2.4% | -12.9% | -0.9% |
| 1Y | 49.8% | 34.9% | 24.4% |
Ritorno vs Industria: JNJ ha superato il US Pharmaceuticals che ha restituito 34.9 % nell'ultimo anno.
Rendimento vs Mercato: JNJ ha superato il mercato US che ha restituito 24.4 % nell'ultimo anno.
Volatilità dei prezzi
| JNJ volatility | |
|---|---|
| JNJ Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: JNJ non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 2% ) di JNJ è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1886 | 138,200 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, insieme alle sue consociate, è impegnata nella ricerca e nello sviluppo, nella produzione e nella vendita di una serie di prodotti nel settore sanitario a livello mondiale. Opera in due segmenti, Medicina innovativa e MedTech. Il segmento Medicina innovativa offre prodotti per diverse aree terapeutiche, quali oncologia, immunologia, neuroscienze, ipertensione polmonare, malattie infettive e cardiovascolari e metabolismo, distribuiti attraverso rivenditori, grossisti, distributori, ospedali e professionisti del settore sanitario su prescrizione.
Johnson & Johnson Riepilogo dei fondamenti
| JNJ statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$545.74b |
| Utili (TTM) | US$21.04b |
| Ricavi(TTM) | US$96.36b |
25.9x
Rapporto P/E5.7x
Rapporto P/SJNJ è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| JNJ Conto economico (TTM) | |
|---|---|
| Ricavi | US$96.36b |
| Costo del fatturato | US$30.80b |
| Profitto lordo | US$65.56b |
| Altre spese | US$44.52b |
| Utili | US$21.04b |
Ultimi utili riportati
Mar 29, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 8.74 |
| Margine lordo | 68.04% |
| Margine di profitto netto | 21.83% |
| Rapporto debito/patrimonio netto | 67.7% |
Come si è comportato JNJ nel lungo periodo?
Vedi performance storica e confrontoDividendi
2.4%
Rendimento attuale del dividendo60%
Rapporto di remunerazioneJNJ paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di JNJ| Johnson & Johnson date dei dividendi | |
|---|---|
| Data di stacco del dividendo | May 26 2026 |
| Data di pagamento dei dividendi | Jun 09 2026 |
| Giorni fino al dividendo Ex | 9 days |
| Giorni prima della data di pagamento dei dividendi | 23 days |
JNJ paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di JNJAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/17 01:09 |
| Prezzo dell'azione a fine giornata | 2026/05/15 00:00 |
| Utili | 2026/03/29 |
| Utili annuali | 2025/12/28 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Johnson & Johnson è coperta da 53 analisti. 23 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |